Efficiency of tivortin in pregnant with heart failure

Authors

  • А. Ю. Ліманська Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine,
  • Ю. В. Давидова Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine, Ukraine
  • В. А. Слободський National Scientific Centre «Institute of Cardiology named after academic M.D. Strazhesko» of the NAMS of Ukraine, Ukraine
  • Л. П. Бутенко Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2014.18.66-70

Keywords:

heart failure, pregnancy, vascular endothelium, nitric oxide, L-arginine, Tivortin

Abstract

The study on the participation of 40 pregnant women with heart failure degree II-III according to NYHA classification on a background of cardiovascular disease (congenital heart disease, hypertension) who received standard therapy of heart failure was performed. All pregnant women were divided into 2 groups of 20 pregnant women in each group. In the main group, which included women with low levels of vascular endothelial growth factor (VEGF) in the first trimester of gestation (indicates a disturbance of the endothelial function), to the basic treatment of heart failure received supplemental arginine hydrochloride (drug Tivortin). The drug was administered by intravenous injection 4,2% 100 ml for 5 days followed by oral solution 5 ml 3-4 times a day, 10 days in the hospital
and continue for 3-4 weeks during the stay at home. Women in the comparison group continued to receive standard therapy.
The results showed that the addition Tivortin to the basic treatment of pregnant women with heart failure improve quality of life, improve overall health, increase exercise tolerance, increased glomerular filtration rate, reduce the rate of vasoconstrictor endothelin. This significantly improves the results of treatment of heart failure during pregnancy.

Author Biographies

А. Ю. Ліманська, Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine

PhD, senior researcher, Obstetric Problems of Extragenital Pathology Department

Ю. В. Давидова, Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine

MD, Head of the Obstetrical Problems of Extragenital Pathology Department

В. А. Слободський, National Scientific Centre «Institute of Cardiology named after academic M.D. Strazhesko» of the NAMS of Ukraine

PhD, senior researcher Chronic Ischemic Heart Disease Department

Л. П. Бутенко, Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine

Obstetrician-gynecologist of the Pregnant Women with Diseases of the Cardiovascular System Department

References

  1. Babushkina A.V. «L-arginine in terms of evidence-based medicine.» Ukrainian medical chasopis, 6(2009):43-48.
  2. Elski V.N., Vatutin N.T., Kalinkina N.V., Salakhova A.M. «Role in the genesis of endoteliy dysfunction at a genesis of the cardiovascular diseases.» Journal of AMS Ukrainy, 14(2008):51-62.
  3. Slobodsky V.A. «The role of L-arginine in the treatment of patients with cardiovascular disease.» Health Ukrainy, 13-14(2009):62.
  4. Hobbs F.D., Kenkre R.J.E., Roalfe A.K. «Impact of heart failure and left ventricular systolic dysfunction on quality of life. A cross-sectional study comparing common chronic cardiac and medical disorders and representative adult population.» Europe Heart Journal, 23(2002):1867-1876.
  5. Voronkov L.G., Paraschenyuk L.P., Lutsak E.A. «Quality of life in chronic heart failure: topical aspects. Heart failer, № 3(2010):18-23.
  6. Garin O., Ferrer M., Pont A. «Disease- specific health-related quality of life questionnaires for heart failure: a systematic review with meta analyses.»Quality Life Results, 18(1) (2009):71-85.
  7. Mendes de Leon C.F., Grady K.L., Eaton C. «Quality of life in a diverse population of heart failure patients.» J. Cardiopulm. Rehabil. Prev, 29(3) (2009):171-178.
  8. Starnes S.L., Duncan B.W., Kneebone J.M., Rosenthal G.L., Jones T.K., Grifka R.G. et al. «Vascular endothelial growth factor and basic fibroblast growth factor in children with cyanotic congenital heart disease.» J Thorac Cardiovasc Surg, 119(2000):534-539.
  9. Wheeler T., Evans P.W., Anthony F.W., Godfrey K.M., Howe D.T. and Osmond C. «Relationship between maternal serum vascular endothelial growth factor concentration in early pregnancy and fetal and placental growth.» Hum. Reprod., 14(2009): 1619-1623.

Downloads

Published

2014-11-17

How to Cite

Ліманська, А. Ю., Давидова, Ю. В., Слободський, В. А., & Бутенко, Л. П. (2014). Efficiency of tivortin in pregnant with heart failure. REPRODUCTIVE ENDOCRINOLOGY, (18), 66–70. https://doi.org/10.18370/2309-4117.2014.18.66-70

Issue

No. 18 (2014)

Section

Pregnancy and childbirth

License

Copyright (c) 2014 А. Ю. Ліманська, Ю. В. Давидова, В. А. Слободський, Л. П. Бутенко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.